Biotech | August 09, 2021
AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
Subscribe To Our Newsletter & Stay Updated
